IFF Pharma Solutions Brings Next-Gen Excipient Innovations to CPHI Japan 2025

TOKYO--( BUSINESS WIRE )-- IFF (NYSE:IFF) Pharma Solutions will showcase its cutting-edge excipient technologies at CPHI Japan 2025. The IFF Pharma Solutions team will highlight its innovations in oral disintegrating tablets (ODTs), controlled-release formulations, and novel complex formulations at booth 5K-21, Tokyo Big Sight East Halls 4-6, April 9-11.

“IFF Pharma Solutions is committed to redefining drug delivery through material science innovation,” said Frank Zhao, commercial leader, IFF Pharma Solutions, Asia Pacific. “At CPHI Japan, we will showcase technologies designed to elevate patient outcomes while streamlining pharmaceutical production.”

As a global leading pharmaceutical excipient partner, IFF Pharma Solutions will highlight some of its latest innovations, including:

Oral Disintegrating Tablet (ODT) Solutions

• The ODT market is expanding rapidly, requiring tablets that dissolve quickly for easy administration to children and elderly patients. Incorporating super disintegrants into ODT formulations is essential, as these agents enhance dissolution speed and improve patient compliance. Ac-Di-Sol®, a leading super disintegrant, offers equivalent disintegration efficacy to polyvinylpolypyrrolidone (PVPP).

Controlled Release (C) Portfolio

• METHOCEL™ Hydroxypropyl methylcellulose (HPMC): Enables consistent and controlled delivery of medication, enhancing therapeutic efficacy and patient compliance through customizable HPMC.
• ETHOCEL™ Ethylcellulose: Water-resistant barrier coatings for targeted drug delivery and taste masking in modified-release tablets.
• POLYOX™ Polyethylene Oxide: High-swell matrices for osmotic delivery and abuse-deterrent systems, supporting osmotic pump technology and modified-release matrix formulations.

Low-Nitrite Solutions

• As a low-nitrite microcrystalline cellulose solution, Avicel® PH LN reduces nitrosamine formation risks in oral solid dosages, ensuring compliance with Japan’s stringent regulatory standards.
• IFF Pharma Solutions expands its low-nitrite excipient portfolio by introducing Low Nitrite METHOCEL™, tailored to help mitigate the risk of nitrosamine formation in drugs.

Combining its deep expertise in excipients, innovation capabilities, and regulatory services, IFF Pharma Solutions offers an integrated solutions platform for customer support at every step of their formulation journeys. To learn more about our broad portfolio and proven expertise, visit https://pharma.iff.com .

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com , LinkedIn , Instagram and Facebook .

©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, ^SM or ^® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250324122216/en/